ArticleFrontiers in pharmacology2026
Selective biological activity of parthenolide derivatives - stizolin, stizolicin, and izospiciformin - isolated from the leaves of
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Breast cancer is the most frequently diagnosed malignant tumor and one of the leading causes of cancer deaths. Combination therapies, chemotherapy, and hormone therapy have indeed revolutionized the treatment of breast cancer, but they have not eliminated the occurrence of side effects. Among different anticancer strategies, plant-derived compounds appear to play a critical role in both prevention and therapy. They have been utilized in folk medicine for years, revealing anti-inflammatory, antimigraine, and anticancer properties. In particular, parthenolide derivatives have been shown to act as adjuvant agents in the treatment of various malignancies. Especially when provided with modifications that increase their bioavailability and stability. Methods: Here, we present the cell type-selective biological activity of parthenolide derivatives-stizolin, stizolicin, and izospiciformin-isolated from the leaves of Results: The highest biological activity was demonstrated by the stizolin (with the IC50 from 1.3 to 4.3 μg/mL depending on cell line), which exhibited antiproliferative, proapoptotic, and proautophagic properties in the studied breast cancer cells, particularly in the HER2-positive breast cancer cell line (SK-BR-3), demonstrated by PARP1/2 cleavage, Bax/Bcl2 status increase, and confirmed by LC3II/LC3I, mTOR, and p62 proteins alterations. Conclusion: Our results indicate that the studied compounds exhibit compound-dependent biological activity, and selectivity across different molecular subtypes of breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.